Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Heptares Enters Strategic Drug Discovery Collaboration With Pfizer Focused On GPCR Targets Across Multiple Therapeutic Areas

LONDON and BOSTON, November 30, 2015 /PRNewswire/ — Heptares Therapeutics (“Heptares”), the clinical-stage GPCR structure-guided drug discovery and development company and wholly-owned subsidiary of Sosei Group Corporation (“Sosei”; TSE Mothers Index: 4565), announces that it has entered into a strategic drug discovery collaboration with Pfizer Inc. (NYSE: PFE) to research and develop potential new medicines […]

Read More »

Pfizer Inks $1.89 Billion Discovery Deal with Heptares, Takes $33 Million Stake in Sosei

Sosei Subsidiary Heptares Enters Strategic Drug Discovery Collaboration with Pfizer Inc. Focused on GPCR Targets Across Multiple Therapeutic Areas TOKYO–(BUSINESS WIRE)–Sosei Group Corporation (“Sosei”) (TOKYO:4565) today announces that its wholly-owned subsidiary, Heptares Therapeutics has entered into a strategic drug discovery collaboration with Pfizer Inc. (NYSE: PFE) to research and develop potential new medicines directed at […]

Read More »

FDA declines expanded approval for Bristol-Myers’ Opdivo drug

Bristol-Myers Squibb Co said the U.S. Food and Drug Administration declined to approve its immuno-oncology drug, Opdivo, for its expanded use to treat an additional type of advanced skin cancer. Bristol-Myers said it received a so-called complete response letter from the health regulator, which indicated the need for additional data in the BRAF mutated patient […]

Read More »

EU approves Roche’s Cotellic in combo therapy against skin cancer

The European Union gave its green light to Roche’s Cotellic for use in combination with the drug Zelboraf against advanced melanoma, the company said on Wednesday.   Roche is counting on Cotellic to help it revive flagging sales of five-year-old Zelboraf, which dropped 25 percent during the first nine months of 2015. It has been […]

Read More »

Pfizer’s Lyrica shows no relief from post-traumatic nerve pain

Pfizer Inc said its blockbuster pain drug, Lyrica, had failed to show benefit in patients suffering from a type of post-traumatic nerve pain, in a late-stage study. The drug did not lead to pain reduction in patients compared with a placebo, the company said on Wednesday. Currently, there is no approved treatment in the United […]

Read More »

Why Price Gouging May Come to an End

(And a way to save some drug companies from themselves) November 25, 2015 By Karl Thiel for BioSpace.com   Price gouging in the pharmaceutical industry has been much in the news lately. There was, of course, the recent case of Turing Pharma and its 5,400 percent increase on the price on Daraprim, a decades-old drug. […]

Read More »

Research raises questions over ADHD drug effects

Researchers voiced concern on Wednesday about poor quality studies on the popular ADHD treatment Ritalin, saying evidence of some benefits, but also of sleep problems and appetite loss, suggests the drug should be prescribed with caution. Ritalin is sold by Swiss pharmaceutical firm Novartis NOVN.VX, known generically as methylphenidate and also sold under the brand […]

Read More »

FDA rejects Indivior’s nasal spray for opioid overdose

Indivior Plc said on Tuesday the U.S. Food and Drug Administration rejected its nasal spray for the emergency treatment of opioid overdose. The company said it was reviewing the health regulator’s response. These sprays contain naloxone, a drug that has been used to treat opioid overdose for nearly 45 years in injectable forms. Last week, […]

Read More »

FDA approves expanded use of Bristol-Myers’ skin cancer drug

Bristol-Myers Squibb Co said the U.S. Food and Drug Administration had approved the expanded use of its cancer drug, Opdivo, to treat an additional form of advanced skin cancer. Opdivo, first approved in December 2014, raked in worldwide revenue of $467 million in the nine months ended Sept. 30. The drug has been approved for […]

Read More »

Novartis heart failure medicine Entresto wins EU approval

The European Commission has approved Novartis’ Entresto drug for the treatment of adult patients with symptomatic chronic heart failure with reduced ejection fraction, the Swiss drugmaker said on Tuesday.   Entresto is the first new drug in decades for helping patients whose lives are in danger because their hearts cannot pump blood efficiently. Analysts estimate […]

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!

Subscribe

Ad Right Bottom